When the U.S. Food and Drug Administration (FDA) was deciding whether to approve the drug Tavneos several years ago to treat a set of rare autoimmune diseases, but agency experts argued that would be a mistake, according to FDA records.
❓ Unknown
FDA's Internal Disagreements Delay Approval of Tavneos for Autoimmune Diseases
Just now
September 23, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
The FDA faced internal disagreements regarding the approval of the drug Tavneos for rare autoimmune diseases, with experts cautioning against its approval. This situation highlights ongoing regulatory challenges in the pharmaceutical industry. For Iran, this may reflect broader issues of drug availability and regulatory practices that could impact healthcare.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Hours After Trump's Renewed Threat to 'Destroy Iran', Massoud Pezeshkian Arrives in New York
21 min ago •
The U.S. to Build Two Military Bases in Greenland Following New Agreement with Denmark
22 min ago •
Iran's Military Promises Severe Retaliation Against US Threats
35 min ago •
Robert Greenway: Trump as the Apex Predator in U.S.-Iran Relations
36 min ago •